|By PR Newswire||
|January 15, 2014 09:01 AM EST||
OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --
Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.
"I am delighted to welcome Tom at this transformative time for Oxford BioTherapeutics, as the company completes its transition into a fully-fledged oncology product development business," said Bryan Morton, Chairman of Oxford BioTherapeutics. "Dr Reynolds' experience in the oncology field will prove invaluable as we progress our pipeline into the clinic, and in particular his expertise in bringing antibody-drug conjugates to market having led the development and approval of ADCETRIS at Seattle Genetics."
Commenting on his appointment, Thomas C Reynolds MD, PhD, said, "I am highly impressed with Oxford BioTherapeutics' cancer targeting technology, which has continued to mature since my tenure at Seattle Genetics. I am delighted to be able to contribute to the development of the company's exciting antibody-based oncology products."
About Thomas C Reynolds MD, PhD
Dr Reynolds has held a number of senior development roles during his career of over 20 years in the biotechnology industry. Most recently he was Chief Medical Officer at Seattle Genetics, where he had direct oversight of the development and approval of the company's antibody-drug conjugate, ADCETRIS. Prior to this, he was Vice President for Medical Affairs at Zymogenetics, having held the role of Senior Medical Director. Previously, he held a number of senior roles at Targeted Genetics Corporation, culminating in the position of Vice President, Clinical Affairs. He began his industry career at Somatix Therapy Corporation as a Research Scientist. Dr Reynolds gained his MD at Stanford University, where he subsequently conducted postdoctoral research. He also holds a PhD in Biophysics from Stanford University, and a degree in Chemistry from Dartmouth College.
About Oxford BioTherapeutics
Oxford BioTherapeutics is developing a range of antibody-drug conjugates for cancer, based on its OGAP® oncology targeting technology. The OGAP® system incorporates one of the world's largest proprietary proteomic databases, with data on 7,500 cancer cell proteins providing unique, highly-qualified therapeutic targets. The company has established collaborations with leading antibody and cancer toxin technology companies, including Seattle Genetics, to build an in-house pipeline of antibody-drug conjugates (ADCs) against a number of these novel targets. In 2012, Oxford BioTherapeutics entered a strategic agreement to accelerate the development of its ADCs, with partner Menarini providing clinical and manufacturing expertise and investment of up to $1 billion in exchange for commercial rights to the treatments outside the US and Japan.
Oxford BioTherapeutics is based in Oxford, UK and San Jose, CA, and has a strong management team with significant experience of developing antibody-based therapies. The company has completed a number of funding rounds, and is supported by a syndicate of specialist venture capital investors. For more information please visit http://www.oxfordbiotherapeutics.com.
Dr Christian Rohlff
David Dible / Sita Shah
Citigate Dewe Rogerson
SOURCE Oxford BioTherapeutics